Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 1,401–1,500 of 2,656
Wu, J., Tseng, K.-J., Kao, C., Hung, K., Yu, T., & Lin, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1652863 · Cited by 3
Ding, Y., Chen, C., Yang, B., Ding, K., & Wang, H. (2026) · BMC Public Health · doi:10.1186/s12889-026-26276-w · Cited by 3
“Although our descriptive design cannot identify causal mechanisms, the patterns are consistent with the need for earlier CKD identification, optimized cardio-kidney-metabolic management, equitable access to kidney-protective therapies, and timely planning for kidney replacement care [1, 24–28].”
Metabolic Checkpoints in IgA Nephropathy: From Pathogenesis to Precision Medicine
Liu, H., Yao, Y., Zhang, C., & Xiong, J. (2026) · Drugs · doi:10.1007/s40265-026-02283-4 · Cited by 2
Diabetic Kidney Disease: From Pathophysiology to Treatment Perspectives
Varda, L., Vreča, N., Ekart, R., Bevc, S., & Piko, N. (2026) · Kidney & Blood Pressure Research · doi:10.1159/000550085 · Cited by 15
Application of SGLT2 inhibitors in kidney diseases: a bibliometric analysis
Hu, Q., Jin, H., Li, X., & Hu, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1768225 · Cited by 3
“The EMPA-KIDNEY trial further confirmed the efficacy of empagliflozin in non-diabetic CKD, showing consistent renoprotection across varying levels of proteinuria and stages of kidney function (14).”
Isawi, I. H., Al‐Sawalha, N. A., Mahmoud, F., Al-Khawaldeh, I., & Alzoubi, K. H. (2026) · Journal of Experimental Pharmacology · doi:10.2147/jep.s561692 · Cited by 2
“19,20 24 Empa has been shown to improve clinical outcomes and reduce mortality in diabetic patients with cardiovascular and chronic kidney diseases, 25–28 while also decreasing inflammation and oxidative stress biomarkers in patients with heart failure.”
Groothof, D., Shehab, N. B. N., Post, A., Erler, N. S., Gans, R. O. B., & Bakker, S. J. L. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101297 · Cited by 3
More than Glucose Elimination: Additional Benefits of SGLT2 Inhibitors in Glomerular Diseases
Vecchio, L. D., Fernández‐Fernández, B., Fornoni, A., Kronbichler, A., & Ortiz, A. (2026) · Drugs · doi:10.1007/s40265-026-02286-1 · Cited by 2
Singh, B., Suarez, M. L. G., Baweja, R., Abulseoud, O. A., Saunders, E. F. H., Frye, M. A., & Baweja, R. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261423437 · Cited by 3
Shao, S., Tsai, D. H., Chuang, A. T.-M., Liu, K., & Lai, E. C. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1004968 · Cited by 5
Omachi, S., Sugahara, S., Horiguchi, J., Yasuda‒Yamahara, M., Kuwagata, S., Yamahara, K., Tanaka‒Sasaki, Y., Ida, S., Kusaba, T., Humphreys, B. D., et al. (2026) · The FASEB Journal · doi:10.1096/fj.202503908r · Cited by 3
Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors
Falsetti, L., Tarquinio, N., Mucci, L., Santini, S., Guerrieri, E., Giovenali, L., Pierdomenico, G., Zaccone, V., Viticchi, G., & Moroncini, G. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04023-9 · Cited by 3
Catanese, B. P., Miller, C., Wolf, M. S., & Edmonston, D. L. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001061 · Cited by 3
Sun, K., & Sun, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1728415 · Cited by 2
Evidence on SGLT2 Inhibitors’ Efficacy in Older and Frail Patients
Kochanowska, A., Mamcarz, A., & Wełnicki, M. T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062219 · Cited by 7
Cherney, D. Z. I., Bonefeld, K., Crater, G., Dwyer, J. P., Frenkel, O., Furberg, J. F., Knop, F. K., Kunos, G., Lalonde, K., Wheeler, D. C., et al. (2026) · Kidney International · doi:10.1016/j.kint.2026.02.023 · Cited by 3
Novel protein biomarkers for risk stratification and personalized medicine
Moedt, E., Ju, W., Nair, V., Bjornstad, P., Kretzler, M., & Heerspink, H. J. L. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag068 · Cited by 3
Chronic Kidney Disease Screening in Patients With Coronary Heart Disease
Al-Azzawy, S. M., Bacquer, D. D., McEvoy, J. W., Adamska, A., Backer, G. D., Erlund, I., Ganly, S., Jennings, C. S., Kotseva, K., Lip, G. Y. H., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.01.075 · Cited by 3
Hua, J., Wang, Q., Liu, Y., Luo, S., Shi, A., Yan, Z., Zhang, J., Gu, W., Zhu, L., Zhang, Y., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03173-5 · Cited by 4
“…causes after 2.0 years of follow-up (HR 0.72, 95% CI 0.64–0.82; P < 0.001), as well as a lower hospitalization rate compared to the placebo group (HR 0.86, 95% CI 0.78–0.95; P = 0.003) [182], and no significant difference was observed in the baseline cardiovascular risk spectrum [183].”
InfluentialOut-of-Pocket Spending for Insulin by Medicare Beneficiaries After Monthly Caps
Hong, D., Cantos, K., Morgenstern, D., Dasgupta, S., Kesselheim, A. S., Song, Z., Tong, A. Y., Chadaram, R., Potter, D. M., Patorno, E., et al. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2026.0255 · Cited by 5
Lin, B.-H., Huang, H., Lin, H., & Lin, S. (2026) · Epilepsia · doi:10.1002/epi.70239 · Cited by 3
Mohsen, M., Yi, T. W., Faruque, L. I., Ke, C., Cafazzo, J. A., Pham, Q. N., Sridhar, V. S., Levin, A., Abdel-Qadir, H. M., Persson, F., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag163 · Cited by 6
Vettor, R., Petroni, M. L., Dotan, I., Lalazar, G., Haluzík, M., Spearman, C. W., Dave, J. A., Abaalkhail, F. A., Abusnana, S., Alshehri, A. A., et al. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10027-8 · Cited by 6
“In addition, empagliflozin lowered the risk of kidney disease progression or cardiovascular death by 28% in a similar population [128].”
Geraci, G., Sinatra, N., Paternò, V., Calabrese, V., Cassataro, G., Cuttone, G., Geraci, C., Esposito, R., Mancusi, C., Pucci, G., et al. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07890-7 · Cited by 3
“…(SGLT2) inhibitors repre - sented a paradigm shift in cardiorenal medicine, as pivotal trials such as CREDENCE, DAPA-CKD, and EMPA-KID - NEY demonstrated robust reductions in both kidney disease progression and cardiovascular events across diabetic and non-diabetic populations [ 8–10].”
SGLT2 Inhibitors in Alzheimer’s Disease: Biochemical Insights and Therapeutic Potential
Mazzeo, P., Vietri, M., Tecce, N., Delizia, A., Remondelli, V., Ciaglia, T., Dio, A. D., Corletti, L., Pizzuti, C. G., Pepe, G., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27115051 · Cited by 2
“Similarly, the EMPA-KIDNEY study demonstrated that empagliflozin consistently reduced the progression of kidney disease or death from cardiovascular causes (Table 2) [13,35,37].”
Kidney-Vascular Metabolic Crosstalk: Altered Lipoproteins in CKD
Saum, K. L., Pennathur, S., & Kanter, J. E. (2026) · Circulation Research · doi:10.1161/circresaha.126.327361 · Cited by 3
Gugliandolo, S., Morciano, C., Guarneri, A., Sorice, G. P., Giaccari, M., Cappannoli, L., Capece, U., Splendore, A., AVOLIO, A., Greco, L. D., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71026 · Cited by 2
Habas, E., Rayani, A., Habas, A., Alarbi, K., Habas, A., Baghi, M., Habas, E., Errayes, E., Hamad, A., & Elzouki, A. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2688578 · Cited by 2
Lv, R., Peng, L., Xu, Y., Du, X., Liu, H. X., Wu, H., Zhang, Y., Li, Q., Jiao, X., Piao, C., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104045 · Cited by 3
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 33
Lupusnephritis – von der Diagnose zur Therapie
Weinmann‐Menke, J. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01489-y · Cited by 2
van der Hoek, S., Koomen, J. V., van Bommel, E. J. M., Mosterd, C. M., Scholtes, R. A., Hesp, A. C., Stevens, J., van Raalte, D. H., & Heerspink, H. J. L. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050747 · Cited by 4
The emerging pillars of chronic kidney disease: no longer a bystander in metabolic medicine
Wonnacott, A. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-rm1 · Cited by 4
Kwiendacz, H., Nabrdalik, K., Czupryniak, L., Klupa, T., Malecki, M. T., Myśliwiec, M., Strojek, K., & Gumprecht, J. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02567-1 · Cited by 2
Schechter, M., Cohen, C. M., Zelter, T., Yanuv, I., Rozenberg, A., Chodick, G., Karasik, A., & Mosenzon, O. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15172 · Cited by 2
“However, these studies included patients with T2D and high cardiovascular risk, or patients with CKD with and without T2D.(8,9) Whether SGLT2 inhibitor use is associated with a lower risk for any hospitalization in a general population of patients with T2D, especially patients without CKD, is unknown.”
BackgroundInfluentialA Narrative Review of Signaling Pathway and Treatment Options for Diabetic Nephropathy
Semwal, B. C., Chauhan, N. S., Jyot, V., Kumar, A., Sonia, S., & Bhupendra, S. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230727093911 · Cited by 3
Time to Reconsider Ejection Fraction in Heart Failure
Seo, Y. (2023) · JACC Asia · doi:10.1016/j.jacasi.2023.07.001 · Cited by 2
Pitt, B., & Bhatt, D. L. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.08.007 · Cited by 2
Noh, J. (2023) · Journal of Korean Diabetes · doi:10.4093/jkd.2023.24.3.127 · Cited by 2
Ghosal, S., Ghosal, S., & Ghosal, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206462 · Cited by 2
Serowik, T. C., & Pantalone, K. M. (2023) · Journal of Osteopathic Medicine · doi:10.1515/jom-2023-0179 · Cited by 5
Koshino, A., Neuen, B. L., Oshima, M., Toyama, T., Hara, A., Arnott, C. G., Neal, B. C., Jardine, M., Badve, S. V., Mahaffey, K. W., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.11.024 · Cited by 3
2023 Update in ambulatory general internal medicine
Alexander, J. T., Singh, S. K., Shah, S. D., Lambert, B., & Smith, J. P. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23056 · Cited by 2
Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease
Khater, J., Malakouti, S., Khoury, A. E., & Cortese, B. (2024) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001598 · Cited by 2
Marstrand-Jørgensen, A. B., Sembach, F. E., Bak, S. T., Ougaard, M., Christensen‐Dalsgaard, M., Madsen, M. R., Jensen, D. M., Secher, T., Heimbürger, S. M. N., Fink, L. N., et al. (2024) · The Nephron journals/Nephron journals · doi:10.1159/000535918 · Cited by 4
Early and Late Stages of Chronic Kidney Disease in Relation to Arterial Changes
Laučytė-Cibulskienė, A., & Gottsäter, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15512-3.00020-9 · Cited by 2
Zhu, X., Li, X., Yin, D., Yang, J., & Wei, R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01560-3 · Cited by 4
Nephrotic syndrome: treatment and prevention of complications
Moiseev, S. V., Bobkova, I. N., Chebotareva, N. V., & Bulanov, N. M. (2024) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2024-1-4-14 · Cited by 2
PROMOVENDO QUALIDADE DE VIDA EM CUIDADOS PALIATIVOS
Mansur, F. H., Pereira, J. S. V., & Teixeira, D. S. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408926 · Cited by 2
Николаевна, К. О., Korotkov, D. A., Sazhina, A. S., & Bogomolov, A. N. (2024) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2024-3014 · Cited by 3
Early Renal Dysfunction in Middle-Aged Adults Predicts Fatal and Nonfatal Cardiovascular Events
Chan, Y., Zhao, J. V., Yeung, S. L. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.029 · Cited by 2
Halimi, J., Sarafidis, P. A., Azizi, M., Bilo, G., Burkard, T., Bursztyn, M., Camafort, M., Chapman, N., Cottone, S., Backer, T. L. M. D., et al. (2024) · Blood Pressure · doi:10.1080/08037051.2024.2368800 · Cited by 2
“…acute kidney injury ( p = .5830), hyperkalaemia ( p = .0649); management of mild to moderate hyperkalaemia: lowering dose of RASb ( p = .6497), use of lowering potassium drugs ( p = .4081), no change in the dose of RASb ( p = .1881); uncontrolled hypertension among CKD patients ( p = .7933)).”
Abdelaziz, A. A., Hafez, A. H., Abdelaziz, M., et al. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.05.007 · Cited by 2
Benedikt, M., Aziz, F., Fröschl, T., Strohhofer, C., Kolesnik, E., Tripolt, N. J., Pferschy, P. N., Wallner, M., Bugger, H., Zirlik, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-64175-5 · Cited by 3
SGLT-2 inhibitors in heart failure: a literature review on mechanisms, efficacy and safety
Kułak, K. B., Chamera-Cyrek, K., Janik, I., Kuśmierska, M., Koman, A. M., Pliszka, M., Gadżała, K., Palacz, K. A., Sztybór, I., & Przygodzka, S. (2024) · Quality in Sport · doi:10.12775/qs.2024.15.52083 · Cited by 3
“In a randomized controlled trial of a diverse group of chronic kidney disease patients susceptible to disease advancement, treatment with empagliflozin resulted in a reduced likelihood of kidney disease progression or cardiovascular-related mortality compared to receiving a placebo [59].”
BackgroundAdvances in the management of chronic kidney disease – a South African perspective
Jardine, T., Davids, M. R., & Chothia, M.-Y. (2024) · Wits Journal of Clinical Medicine · doi:10.18772/26180197.2024.v6n2a6 · Cited by 2
Understanding the interplay between chronic lymphocytic leukemia and type 2 diabetes
Vainer, N., Curovic, V. R., Niemann, C. U., Slager, S. L., & Rotbain, E. C. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2383417 · Cited by 4
Chan, G. C., Ng, J. K., Szeto, C., & Chow, K. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111818 · Cited by 2
Inibidores de SGLT2 e inflamassoma NLRP3: alvo potencial na doença renal do diabetes
Júnior, P. A. B. M., Lass, A. D., Pilger, B. I., Fornazari, R., de Moraes, T. P., & Pinho, R. A. (2024) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2023-0187pt · Cited by 6
Bai, S., Lin, C., Cai, X., Wu, H., Jiao, R., Hu, S., Lv, F., Yang, W., & Ji, L. (2024) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12646 · Cited by 2
Update on Sodium Glucose Cotransporter Type 2 Inhibitors Use in Kidney Transplant Patients
Salvadori, M., Rosati, A., & Rosso, G. (2024) · Transplantology · doi:10.3390/transplantology5030022 · Cited by 2
Huttunen, R., Haapanen-Saaristo, A.-M., Hjelt, A., Jokilammi, A., Paatero, I., & Järveläinen, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117453 · Cited by 3
Ghukasyan, H., Navalha, D. D. P., Romero, I. P., Wolwacz, M. V. P., Ghahramanyan, A., Ngan, C. W. T., de Melo, M. H. S. T., Dagostin, C. S., & Quirós, L. G.-L. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.06.004 · Cited by 2
Chang, T., Lee, Y., Wu, L., & Chang, C. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4615 · Cited by 6
Dapagliflozin for rheumatic musculoskeletal disease in patients with chronic kidney disease
Hanaoka, H., Kikuchi, J., Hiramoto, K., Akiyama, M., Saito, S., Kondo, Y., Azegami, T., & Kaneko, Y. (2024) · Modern Rheumatology · doi:10.1093/mr/roae090 · Cited by 2
Cheng, Y., Chan, Y., Chuang, C., Chen, S., Chao, T., & Kao, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16011 · Cited by 3
Liao, J., Chen, Y., Ling, Z., Pürerfellner, H., Martinek, M., Derndorfer, M., Niel, J., Ebrahimi, R., Heukäufer, M., Janschel, S., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15136 · Cited by 2
Seasonal variations in the association between proteinuria and kidney failure
Kawaoka, T., Sakaguchi, Y., Oka, T., Asahina, Y., Hattori, K., Doi, Y., Hashimoto, N., Kusunoki, Y., Yamamoto, S., Yamato, M., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae278 · Cited by 2
Naami, R., Miller, D. M., Datla, S., Rahman, M. U., Al-Kindi, S. G., & Neeland, I. J. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000746 · Cited by 5
Ferrannini, E., Baldi, S., Scozzaro, T., Ferrannini, G., & Hansen, M. K. (2024) · JCI Insight · doi:10.1172/jci.insight.180637 · Cited by 3
“…reflected by the beneficial class effects of SGLT2i on the heart and the kidney which, after the landmark cardiovascular outcome trials in patients with T2D, are now established even in patients with HF and without T2D (23, 24) and in patients with CKD regardless of the presence of T2D (25, 26).”
Lu, D., Zheng, R., Li, A., & Zhang, J. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.98552 · Cited by 3
Kim, N. H., Lim, S. K., Jeong, I., Rhee, E., Moon, J. S., Ryu, O., Kwon, H., Won, J. C., Kim, S. S., Kim, S. Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0238 · Cited by 2
Antihypertensive and renal protection effects of lercanidipine and lercanidipine/enalapril
Ferri, N., Corsini, A., & Pontremoli, R. (2024) · European Atherosclerosis Journal · doi:10.56095/eaj.v3i3.58 · Cited by 2
“…action, has been determined to be more potent with ACE inhibitors or angiotensin receptor blockers (ARBs), and more recently by gliflozins [9, 10], compared with first-or second-generation CCBs, likely because these latter agents cause a preferential dilation of the glomerular afferent…”
Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Kidney Disease and beyond
Hannouneh, Z. A., Cervantes, C. E., Hanouneh, M. A., & Atta, M. G. (2025) · Glomerular Diseases · doi:10.1159/000543685 · Cited by 4
Yoshida, Y., & Shibata, H. (2025) · Hypertension Research · doi:10.1038/s41440-025-02162-7 · Cited by 2
Sellasie, S. W., Pecchioli, C., Cersosimo, K., Nardone, I., Zaccaria, S., Centi, A., Perna, P., Tatangelo, P., Sperti, P., Schifano, G., et al. (2025) · Acta Diabetologica · doi:10.1007/s00592-024-02423-w · Cited by 2
Hypertension in chronic kidney disease and future heart failure
Burnier, M. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001206 · Cited by 2
Julián, M. T., Codina, P., Lupón, J., Zamora, E., de, A. P.-M., Domingo, M., Santiago‐Vacas, E., Borrellas, A., Ruiz-Cueto, M., González-Gallego, C., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02632-9 · Cited by 6
“Large-scale clinical trials have shown that novel glucose-lowering drugs, such as SGLT2i, offer benefits beyond glycaemic control, such as reducing important renal endpoints and slowing the annual decline in eGFR in populations with and without T2D [1, 52–54].”
Jimba, T., Kaneko, H., Suzuki, Y., Okada, A., Azegami, T., Ko, T., Fujiu, K., Morita, H., Takeda, N., Hayashi, K., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf156 · Cited by 3
Need for life cycle assessment of pharmaceuticals for kidney healthcare
Nagai, K., & Nansai, K. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02647-2 · Cited by 2
“Among these, drugs that are often administered for their kidney protective effects include RAS (renin–angiotensin system) inhibitors [77], and SGLT2 (sodium-glucose cotransporter 2) inhibitors [78, 79].”
Kano, Y., Tanabe, K., Kitagawa, M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320482 · Cited by 2
Updates in chronic kidney disease management: A systematic review
Ammar, A., Edwin, S. B., Whitney, R., Lipari, M., & Giuliano, C. A. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70014 · Cited by 3
Kim, H. (2025) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2025.5.e4 · Cited by 2
Shah, M. U., Roebuck, A., Srinivasan, B., Squires, P. E., Hills, C. E., Inghels, M., & Lee, K. (2025) · Diabetic Medicine · doi:10.1111/dme.70030 · Cited by 4
6. Cardio-renal protection in type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112150 · Cited by 6
Gajić, S., Janković, S., Stojadinovic, M. M., Filić, K., Bontić, A., Pavlović, J., Mrđa, I., Petrović, K., Hadži-Tanović, L., Žunić, J., et al. (2025) · Metabolites · doi:10.3390/metabo15040271 · Cited by 3
Aortic valve calcium as a novel risk marker for kidney function deterioration: The MESA study
Abdollahi, A., Sani, M. M., Shabani, M., Matuck, B. S., Blaha, M. J., Wu, C. O., Ambale‐Venkatesh, B., Budoff, M. J., Strom, J. B., Rotter, J. I., et al. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.03.037 · Cited by 2
Cockroach allergen exposure alters redox homeostasis and mediates airway inflammation
Sharma, S., Nagar, E., & Arora, N. (2025) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2025.104438 · Cited by 2
Llorens, P., Haro, A., Gil, V., et al. (2025) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2025.502300 · Cited by 2
Song, S., Guo, Y., Lin, Y., Gao, H., & Ren, H. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01753-4 · Cited by 4
“For example, the EMPA-KIDNEY trial confirmed that empagliflozin substantially decreased the risk of kidney disease advancement and the development of ESRD in patients with CKD, with or without diabetes [25].”
Carroll, O., Bidulka, P., Basu, A., Adler, A., O’Neill, S., Briggs, A. H., Lugo-Palacios, D. G., Khunti, K., & Grieve, R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16447 · Cited by 4
Górriz, J. L., Gil, F. A., López, M. A. B., Soto, A. B., Cabrera, F. J. C., Cisneros, A., Guerrero, S. C., Conejos, M. D., Cabello, I. E., Planelles, M., et al. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.05.001 · Cited by 3
The diagnostic status of chronic kidney disease in a real-world database in Japan: CHECK-CKD
Moriyama, T., Kanafuri, K., Kanno, M., Niibe, K., Nago, S., Fukuoka, I., Fukunaga, Y., Doi, I., & Kawashima, M. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02682-z · Cited by 2
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.06.015 · Cited by 4
Hung, T., Lin, T., Liou, Y., Lin, T., Hsu, Y., Lin, L., & Wang, M. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20112 · Cited by 2
Evaluation and Management of Obesity in Chronic Kidney Disease
Friedman, A. N. (2025) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2025.07.004 · Cited by 4
Kawahara, T., Toda, M., Kanagawa, M., Toyama, N., Suzuki, G., Kawahara, C., & Inazu, T. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s547088 · Cited by 4
“4 Consequently, the use of SGLT-2is has expanded across multiple fields.”
Integration of Genetics Into the Design and Conduct of Clinical Trials in Nephrology
Ozimek-Kulik, J. E., Larkins, N., Rangan, G. K., & McCarthy, H. J. (2025) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2025.151650 · Cited by 3
Truth and Pitfalls of Evidence-Based Medicine
Campese, V. M. (2025) · Kidney and Dialysis · doi:10.3390/kidneydial5030038 · Cited by 3
Yang, I., Chong, K.-S., Peng, Z., Ou, H., & Wang, M.-C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112427 · Cited by 4
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.